ATE132190T1 - Hemmung von htlv-iii durch exogene oligonukleotide - Google Patents

Hemmung von htlv-iii durch exogene oligonukleotide

Info

Publication number
ATE132190T1
ATE132190T1 AT89903415T AT89903415T ATE132190T1 AT E132190 T1 ATE132190 T1 AT E132190T1 AT 89903415 T AT89903415 T AT 89903415T AT 89903415 T AT89903415 T AT 89903415T AT E132190 T1 ATE132190 T1 AT E132190T1
Authority
AT
Austria
Prior art keywords
htlv
iii
inhibition
exogeneous
oligonucleotides
Prior art date
Application number
AT89903415T
Other languages
English (en)
Inventor
John Goodchild
Paul C Zamecnik
Sudhir Agrawal
Original Assignee
Worcester Found Ex Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Found Ex Biology filed Critical Worcester Found Ex Biology
Application granted granted Critical
Publication of ATE132190T1 publication Critical patent/ATE132190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89903415T 1988-02-26 1989-02-24 Hemmung von htlv-iii durch exogene oligonukleotide ATE132190T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16057488A 1988-02-26 1988-02-26

Publications (1)

Publication Number Publication Date
ATE132190T1 true ATE132190T1 (de) 1996-01-15

Family

ID=22577455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89903415T ATE132190T1 (de) 1988-02-26 1989-02-24 Hemmung von htlv-iii durch exogene oligonukleotide

Country Status (6)

Country Link
EP (1) EP0402402B1 (de)
JP (1) JPH04501052A (de)
AT (1) ATE132190T1 (de)
AU (1) AU636573B2 (de)
DE (1) DE68925278T2 (de)
WO (1) WO1989008146A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2029273A1 (en) * 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
WO1992005284A1 (en) * 1990-09-21 1992-04-02 University Of Maryland Compositions and methods for inhibiting growth or replication of viruses
AU652006B2 (en) * 1990-10-09 1994-08-11 Nexstar Pharmaceuticals, Inc. Inhibition of viral replication
HUT64554A (en) * 1990-11-20 1994-01-28 Sankyo Co A process for preparing nucleinic acide derivatives of anesthetic effect and pharmaceutical compositions containing them as active ingredient
JPH06506599A (ja) * 1991-04-05 1994-07-28 エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー パッケージング配列に相補的なアンチセンス核酸によるレトロウイルスの抑制
ES2103918T3 (es) * 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5332814A (en) * 1991-11-12 1994-07-26 Ciba-Geigy Corporation Process for the preparation of carbacyclic nucleosides, and intermediates
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
EP0577558A2 (de) * 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
AU678769B2 (en) * 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
WO1994008004A1 (en) * 1992-10-05 1994-04-14 Hybridon, Inc. Therapeutic anti-hiv oligonucleotide and pharmaceutical
DK0626387T3 (da) * 1993-05-12 1999-09-27 Novartis Ag Nukleosider og oligonukleotider med 2'-ethergrupper
EP0707653B1 (de) * 1993-06-11 2004-09-01 Commonwealth Scientific And Industrial Research Organisation Methode der spezifischen abschaltung von genen durch dna-methylierung
AU697234B2 (en) * 1993-06-23 1998-10-01 Viventia Biotech Inc. Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
HU220423B (hu) * 1994-01-26 2002-01-28 Novartis Ag. Módosított oligonukleotidok
DE59510742D1 (de) * 1994-04-27 2003-08-14 Novartis Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen
ATE188479T1 (de) 1994-06-01 2000-01-15 Hybridon Inc Verzweigte oligonukleotide als pathogenhemmende mittel
GB9415129D0 (en) * 1994-07-27 1994-09-14 Lynxvale Ltd Oligonucleotides and their use
DE4427219A1 (de) * 1994-08-01 1996-02-08 Max Planck Gesellschaft Nukleinsäure zur Initiation der Aktivität von RNase H bzw. reverser Transkriptase
CA2197788A1 (en) * 1994-09-02 1996-03-14 Robert Haner Functional terpyridine metal complexes, methods for their preparation and oligonucleotide conjugates with terpyridine metal complexes
GB9604669D0 (en) 1996-03-05 1996-05-01 Ciba Geigy Ag Chemical compounds
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
DE19739956C1 (de) * 1997-09-11 1998-07-02 Horst Prof Dr Domdey tRNA-Primer, seine Herstellung und Verwendung zur Inhibierung der reversen Transkriptase
GB0012497D0 (en) * 2000-05-23 2000-07-12 Syngenix Ltd Antiviral therapy
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
EP1647595A1 (de) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nukleinsäuren gegen Viren, insbesondere gegen HIV
JP5155176B2 (ja) 2005-11-17 2013-02-27 ティーイーティー システムズ ゲーエムベーハー ウント ツェーオー． カーゲー 誘導発現系
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
DK1974017T4 (da) 2005-12-09 2023-09-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
ES2626671T3 (es) 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477994B1 (de) * 1985-03-21 2001-06-13 Johnston, Stephen, Ph.D. Von Parasit gewonnener Widerstand
EP0252940A4 (de) * 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Antisense-rna zur behandlung von retroviralen krankheiten.
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
ZA902912B (en) * 1989-04-21 1991-01-30 Cornell Res Foundation Inc Method of inhibiting induction of latent or chronic viral infection

Also Published As

Publication number Publication date
AU4072089A (en) 1989-09-22
DE68925278T2 (de) 1996-09-19
WO1989008146A1 (en) 1989-09-08
AU636573B2 (en) 1993-05-06
JPH04501052A (ja) 1992-02-27
DE68925278D1 (de) 1996-02-08
EP0402402A1 (de) 1990-12-19
EP0402402B1 (de) 1995-12-27

Similar Documents

Publication Publication Date Title
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
ATE112310T1 (de) Hemmung von htlv-iii durch exogene oligonukleotide.
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
AU8771398A (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
FI925103A0 (fi) Antisense-inhibitorer av humant immunbristvirus
BR9206156A (pt) Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS
ES2108748T3 (es) Amplificacion de acidos nucleicos con actividad de rna polimerasa dependiente de dna, de rna replicasas.
DE69129694D1 (de) Hemmung der replikation des influenza-virus durch oligonukleotide
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
NO951307L (no) Terapeutiske anti-HIV oligonukleotider
DE3888425D1 (de) Virale Expressionsinhibitoren.
DE59010432D1 (de) Genetische Einheiten zur Inhibierung der Funktion von RNA
ZA964445B (en) Oligonucleotides specific for hepatitis b virus
ATE163973T1 (de) Antisense oligonukleotidhemmung von papillomavirus
DK0775745T3 (da) Cathepsin G-inhiberende aptamerer
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
EP0578776A4 (de) Hemmung von retroviren mittels zu verpackungssequenzen komplementärer antisense-nukleinsäuren.
Hatta et al. Mechanisms of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotides
HUP0202852A2 (hu) Módosított ubiquitin-szabályozó rendszer
WO2001014576A8 (en) Process and intermediates for the preparation of isoxazolecaroxamides and analogues
WO1996039500A3 (en) Oligonucleotides specific for hepatitis c virus
HRP20050415B1 (en) A process for the purification of 1,4-butanediol mononitrate
KR950023404A (ko) 5-히드록시메틸-2-푸르푸랄을 함유하는 비(b)형 간염 치료제

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee